Navigation Links
Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR

ritis". Additional analysis from the trial indicated that CRx-102 treated patients experienced significantly less fatigue than those on placebo (-27.2mm CRx-102 vs. -14.3mm placebo, p=0.03). Fatigue information was collected on all subjects in the trial and was measured using a visual analog scale (VAS).

"This data on CRx-102 provides additional evidence of its clinical benefit and novel mechanism of action which will prove extremely helpful as we design future studies and more specifically define the clinical benefit of CRx-102 and its potential role within the RA and OA treatment paradigms," commented Alexis Borisy, President and CEO of CombinatoRx.

CRx-139

Also, during the satellite symposium, Dr. Paul Emery of Leeds Teaching Hospital in the UK gave a talk entitled "Inverting the Pyramid, Deploying Smarter Combination Therapies in RA", during which he presented additional analysis from the recently completed phase 2a clinical trial of CRx-139. Dr. Emery showed that subjects treated with high dose CRx-139 (3mg of prednisolone and 20mg of paroxetine) showed a benefit in ACR 50 response compared to low dose CRx-139 (3mg of prednisolone and 10mg of paroxetine) or 3mg of prednisolone alone.

-- ACR 50 at day 42 (32% CRx-139 high dose vs. 13% CRx-139 low dose and 13% 3mg prednisolone, p=0.008)

-- ACR 50 at day 70 (28% CRx-139 high dose vs. 15% CRx-139 low dose and 20% 3mg prednisolone, p=NSS)

Dr. Emery also noted that a subset of the high dose treated patients experienced durable remission defined as DAS28 score of less than 2.6 at consecutive visits (19% CRx-139 high dose vs. 4% CRx-139 low dose and 3% 3mg prednisolone, p=0.026).

About CRx-102

CRx-102 is an oral synergistic combination drug candidate containing the cardiovascular agent dipyridamole and an unconventionally low dose of the steroid prednisolone. CRx-102 works through a novel mechanism of action in which dipyridamole selectively amplifies prednisolone
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
4. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
5. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
6. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:5/4/2015)... 4, 2015  Amgen (NASDAQ: AMGN ) will present ... a.m. ET on Thursday, May 7, 2015, at the InterContinental ... , executive vice president of Global Commercial Operations at Amgen, ... can be accessed from the Events Calendar on Amgen,s website, ... will also be available on Amgen,s website for 90 days ...
(Date:5/4/2015)... DALLAS , May 4, 2015   The ... new injection, Kybella, from internationally acclaimed plastic surgeon, ... Food and Drug Administration, is proven to reduce fat ... http://photos.prnewswire.com/prnh/20150504/213559 The active ingredient in ... and gives plastic surgeons the ability to reshape this ...
(Date:5/4/2015)... Mass. and TORONTO , ... www.generex.com ) (OTCQB:GNBT) today announced that it intends to ... it receives upon completion of a definitive licensing agreement ... Smoofi, Inc. ( www.smoofi.com ) (OTCQB:SMFI). As ... non-binding letter of intent in respect of the licensing ...
Breaking Medicine Technology:Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference 2Dr. Rod Rohrich Provides Medical Expertise on Kybella 2Dr. Rod Rohrich Provides Medical Expertise on Kybella 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5
... a useful and focused trial that builds on the ... best possible care for diabetic patients with chronic stable ... Society for Cardiovascular Angiography and Interventions (SCAI) encourages healthcare ... to their patients, as studied in this trial. ...
... TRIANGLE PARK, N.C., and NEW ORLEANS, June 7 New ... 69th Scientific Sessions in New Orleans show that the investigational ... levels and provided weight loss across weekly, biweekly and monthly ... managing type 2 diabetes, a disease that affects over 250 ...
Cached Medicine Technology:SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine 2SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine 3SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine 4Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 2Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 3
(Date:5/4/2015)... 2015 In May of 2010, after two ... life. In the wake of this tragedy, Ty’s parents Kirk ... that exposes the grim reality of bullying and its devastating ... Kirk and Laura to share their story and offer education ... to another family — a mission that took the Smalley ...
(Date:5/4/2015)... Now in its seventh year, the ... have made outstanding contributions to the company, to their ... acute and post-acute care settings. The five award categories ... the Year, Advanced Practice Clinician of the Year, Newcomer ... Year. Recipients are selected by IPC’s senior management team. ...
(Date:5/4/2015)... City, OK and Seattle, WA (PRWEB) May 04, 2015 ... announced the formation of a collaboration to facilitate development ... number of ophthalmic disorders that lead to blindness, including ... to the MiDROPS™ formulation platform developed by EyeCRO, which ... the eye via a topical eyedrop. , Under ...
(Date:5/4/2015)... SC (PRWEB) May 04, 2015 Ticket Down ... at the Colonial Life Arena in Columbia, South Carolina. ... the continuation of his “Out There” tour which originally kicked ... long tour is North America and the legendary performer recently ... at the Wells Fargo Arena on June 21st, in Charlottesville, ...
(Date:5/4/2015)... 2015 Pricing Healthcare announces it ... one patient receiving care at St. George Surgical Center ... must be performed by July 15th, 2015, and the patient ... up front and forego the filing of insurance claims). , ... every year, and it devastates more and more individuals and ...
Breaking Medicine News(10 mins):Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3
... code for a type of pancreatic cancer, called neuroendocrine or ... 20 issue of Science Express, shows that patients ... as those without them. "One of the most significant ... of rare cancer has a unique genetic code that predicts ...
... Researchers from Upstate New York institutions, including the ... two industrial pollutants in carp in eastern Lake ... demonstrating the lasting environmental effects of human activity ... The two contaminants the scientists studied were polychlorinated ...
... in an 8-week mindfulness meditation program appears to make ... of self, empathy and stress. In a study ... Psychiatry Research: Neuroimaging, a team led by ... their study, the first to document meditation-produced changes over ...
... , FRIDAY, Jan. 21 (HealthDay News) -- Americans suffering from ... in a cream to help soothe their aches. But ... on: analgesics delivered through a medicated patch placed directly where ... the country,s first over-the-counter, pain-relieving transdermal patches in 2008. But ...
... Department of Psychiatry at Case Western Reserve University School of ... National Institute of Mental Health (NIMH) for the long-term study ... the NIMH, one of the National Institutes of Health (NIH), ... in which 707 children between the ages of six and ...
... HealthDay Reporter , THURSDAY, Jan. 20 (HealthDay News) -- ... think vaccines don,t cause autism, a new Harris Interactive/HealthDay ... vaccines, like the measles-mumps-rubella (MMR) vaccine, can cause the disorder, ... conducted last week, following news reports that said the lead ...
Cached Medicine News:Health News:Johns Hopkins scientists crack genetic code for form of pancreatic cancer 2Health News:Johns Hopkins scientists crack genetic code for form of pancreatic cancer 3Health News:Scientists find industrial pollutants in Eastern Lake Erie carp 2Health News:Scientists find industrial pollutants in Eastern Lake Erie carp 3Health News:Mindfulness meditation training changes brain structure in 8 weeks 2Health News:Mindfulness meditation training changes brain structure in 8 weeks 3Health News:Pain Patches Making Gains in U.S. 2Health News:Case Western Reserve receives $7.8M to study manic symptoms in children 2Health News:Case Western Reserve receives $7.8M to study manic symptoms in children 3Health News:Nearly Half of Americans Still Suspect Vaccine-Autism Link 2Health News:Nearly Half of Americans Still Suspect Vaccine-Autism Link 3
Prostate biopsy transducer....
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... Linear high frequency ... breast and superficial ... exclusive Hemispheric Sound ... technologies. This multi-frequency ...
... an excellent choice for a ... wide scan angle. With muliple ... designed for a wide view ... versatility of this transducer provides ...
Medicine Products: